<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720755</url>
  </required_header>
  <id_info>
    <org_study_id>1572819</org_study_id>
    <nct_id>NCT04720755</nct_id>
  </id_info>
  <brief_title>Low Intensity Extracorporeal Shock Wave Therapy (Li-ESWT) for Erectile Dysfunction</brief_title>
  <official_title>Low Intensity Extracorporeal Shock Wave Therapy (Li-ESWT) for Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunter Holmes Mcguire Veteran Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunter Holmes Mcguire Veteran Affairs Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low-intensity extracorporeal shock wave therapy (Li-ESWT) has shown promise as a novel&#xD;
      treatment for erectile dysfunction (ED), though the the mechanism of action and optimal&#xD;
      protocol for administration has not been well-established. The aim of this study is to assess&#xD;
      for subjective and objective improvements in erectile function following treatment with&#xD;
      Li-ESWT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be enrolled as outlined below. Prior to initiation of Li-ESWT&#xD;
      treatments, patients will complete validated questionnaires to assess erectile function. In&#xD;
      addition, patients will undergo induction of artificial erection in clinic with assessment of&#xD;
      penile blood flow using penile Doppler. Intracavernosal pressure measurements will be&#xD;
      obtained. A corporal aspirate will be drawn and examined for levels of neuronal nitric oxide&#xD;
      synthase, endothelial nitric oxide synthase, brain-derived neurotropic factor and vascular&#xD;
      endothelial growth factor. Patients will then receive twice-weekly Li-ESWT treatments of&#xD;
      0.2mJ/mm^2 over 3 treatment sites along the dorsal penile shaft, 1500 shocks per treatment&#xD;
      (500 shocks per treatment site), for a total of 3000 shocks per week, for 6 weeks of&#xD;
      treatment (totally 18,000 shocks). Following Li-ESWT treatments, patients will complete the&#xD;
      same validated questionnaires, penile Doppler studies, corporal aspirates and measurement of&#xD;
      intracavernosal pressures immediately following the final Li-ESWT treatment, 4-6 weeks&#xD;
      following completion of treatment, and again at 3 and 6 months following completion of&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the efficacy of the Storz Duolith SD-1 T-top &gt;&gt;ultra&lt;&lt; Li-ESWT device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>To provide data in support of a standardized protocol for the treatment duration for use of this device in treatment of erectile dysfuntion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>To provide data in support of a standardized protocol for the treatment dose for use of this device in treatment of erectile dysfuntion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of improvements in penile corporal tissues</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate for upregulation of nNOS, eNOS, BDNF and VEGF within penile corporal tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of improvements in penile corporal tissues</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate for improvements in penile blood flow as detectable on penile Doppler and by measurement of intracavernosal pressures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of improvements in penile corporal tissues</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate for improvements in penile blood flow as detectable by measurement of intracavernosal pressures</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive twice-weekly Li-ESWT treatments of 0.2mJ/mm² over 3 treatment sites along the dorsal penile shaft (distal, mid-shaft, proximal), 1500 shocks per treatment (500 shocks per treatment site) for a total of 3000 shocks per week, for 6 weeks (total of 18,000 shocks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low-Intensity Extracorporeal Shock Wave Therapy</intervention_name>
    <description>Twice-weekly treatments for 6 weeks, of 0.2mL/mm^2 administered for 500 shocks per treatment site, for a total of 3000 shocks per week.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Storz Duolith SD-1 t-top &gt;&gt;ultra&lt;&lt; device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male veterans between 40 and 80 years of age&#xD;
&#xD;
          -  Known or suspected vasculogenic erectile dysfunction based on clinical history&#xD;
&#xD;
          -  In an active sexual relationship with a minimum of 2 sexual attempts per month for at&#xD;
             least one month prior to enrollment&#xD;
&#xD;
          -  Suffering from ED for at least 6 months&#xD;
&#xD;
          -  International Index of Erectile Function - EF domain score between 17-25, Erection&#xD;
             Hardness Score score ≥ 1&#xD;
&#xD;
          -  Testosterone level between 300-1000ng/dL within one month prior to enrollment&#xD;
&#xD;
          -  Hgb A1c ≤ 8% within one month prior to enrollment&#xD;
&#xD;
          -  Able to consent to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Erectile dysfunction due to radical prostatectomy, prior pelvic surgery, or radiation&#xD;
             therapy to the pelvis within 12 months prior to enrollment.&#xD;
&#xD;
          -  Men with known neurogenic or psychogenic ED&#xD;
&#xD;
          -  Anatomic malformations of the penis including Peyronie's disease&#xD;
&#xD;
          -  Testosterone &lt; 300ng/dL or &gt;1000ng/dL&#xD;
&#xD;
          -  Hgb A1c &gt; 8%&#xD;
&#xD;
          -  International Normalized Ratio &gt; 2.5, and men on any blood thinners other than 81mg&#xD;
             aspirin&#xD;
&#xD;
        Participants will be required to discontinue all erectogenic medications for 1 months prior&#xD;
        to initiation of treatment and will not be permitted to use erectogenic medications for the&#xD;
        duration of the treatment study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participants must be men with erectile disfunction.</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah C Krzastek, MD</last_name>
    <phone>804-675-5409</phone>
    <email>sarah.krzastek@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VAMC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Krzastek, MD</last_name>
      <phone>904-675-5000</phone>
      <phone_ext>5409</phone_ext>
      <email>sarah.krzastek@va.gov</email>
    </contact>
    <investigator>
      <last_name>Sarah Krzastek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ranjodh Gill, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Young SR, Dyson M. The effect of therapeutic ultrasound on angiogenesis. Ultrasound Med Biol. 1990;16(3):261-9.</citation>
    <PMID>1694604</PMID>
  </reference>
  <reference>
    <citation>Angulo JC, Arance I, de Las Heras MM, Meilán E, Esquinas C, Andrés EM. Efficacy of low-intensity shock wave therapy for erectile dysfunction: A systematic review and meta-analysis. Actas Urol Esp. 2017 Oct;41(8):479-490. doi: 10.1016/j.acuro.2016.07.005. Epub 2016 Aug 10. Review. English, Spanish.</citation>
    <PMID>27521134</PMID>
  </reference>
  <reference>
    <citation>Sokolakis I, Dimitriadis F, Psalla D, Karakiulakis G, Kalyvianakis D, Hatzichristou D. Effects of low-intensity shock wave therapy (LiST) on the erectile tissue of naturally aged rats. Int J Impot Res. 2019 May;31(3):162-169. doi: 10.1038/s41443-018-0064-0. Epub 2018 Aug 17.</citation>
    <PMID>30120384</PMID>
  </reference>
  <reference>
    <citation>Liu T, Shindel AW, Lin G, Lue TF. Cellular signaling pathways modulated by low-intensity extracorporeal shock wave therapy. Int J Impot Res. 2019 May;31(3):170-176. doi: 10.1038/s41443-019-0113-3. Epub 2019 Jan 22. Review.</citation>
    <PMID>30670837</PMID>
  </reference>
  <reference>
    <citation>Lin G, Reed-Maldonado AB, Wang B, Lee YC, Zhou J, Lu Z, Wang G, Banie L, Lue TF. In Situ Activation of Penile Progenitor Cells With Low-Intensity Extracorporeal Shockwave Therapy. J Sex Med. 2017 Apr;14(4):493-501. doi: 10.1016/j.jsxm.2017.02.004. Epub 2017 Mar 1.</citation>
    <PMID>28258952</PMID>
  </reference>
  <reference>
    <citation>Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol. 2010 Aug;58(2):243-8. doi: 10.1016/j.eururo.2010.04.004. Epub 2010 May 6.</citation>
    <PMID>20451317</PMID>
  </reference>
  <reference>
    <citation>Clavijo RI, Kohn TP, Kohn JR, Ramasamy R. Effects of Low-Intensity Extracorporeal Shockwave Therapy on Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med. 2017 Jan;14(1):27-35. doi: 10.1016/j.jsxm.2016.11.001. Epub 2016 Dec 13. Review.</citation>
    <PMID>27986492</PMID>
  </reference>
  <reference>
    <citation>Man L, Li G. Low-intensity Extracorporeal Shock Wave Therapy for Erectile Dysfunction: A Systematic Review and Meta-analysis. Urology. 2018 Sep;119:97-103. doi: 10.1016/j.urology.2017.09.011. Epub 2017 Sep 27.</citation>
    <PMID>28962876</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>Low intensity shock wave therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

